Amit Achhra

Amit Achhra

Auto-generated profile, based on publicly available information

Amit Achhra

Section of Infectious Diseases, Department of Medicine, Yale School of Medicine , New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AAAmit C Achhra
Amit C Achhra
ECElizabeth Chan
Elizabeth Chan
SASerina Applebaum
Serina Applebaum
MGMaggie Guerrero
Maggie Guerrero
RHRitche Hao
Ritche Hao
LBLydia Barakat
Lydia Barakat
Background: Guidelines recommend annual anal cytology-based squamous cell carcinoma of anus (SCCA) screening for men who have sex with men with HIV aged ≥35 years (eligible population). The recommended threshold for high-resolution anoscopy (HRA) depends on its availability: low-threshold (any abnormal cytology) if availability is high and high-threshold (high-grade squamous intraepithelial lesion [HSIL] on cytology) if availability is low. Methods: This was a retrospective chart review (2018–2022) at academic HIV clinics. We evaluated (1) 5-year uptake of cytology-based SCCA screening in the eligible population and (2) estimated HSIL detection rate based on our current low-threshold criteria, and if high-threshold criteria were used for HRA referral. Results: Of 432 eligible individuals, only 219 (50.7%) had at least 1 and only 113 (26%) had >1 SCCA screening tests in a median follow-up of 4 years. Seventy-four (17.1%) individuals had at least 1 abnormal anal cytology during follow-up, of whom 56 (75.6%) underwent HRA. Increasing age (≥57 years) and history of smoking negatively correlated with ever receiving screening. Anal cytology (365 tests in 206 individuals) showed 17.5% “unsatisfactory” and 26.8% with any abnormal cytology (zero with HSIL) triggering HRA referral. Only 34 individuals (7.8% of screening eligible) were ever detected with HSIL. Strictly using high-threshold criteria for HRA referral would have led to no HRA or HSIL detection. Conclusions: We noted poor uptake of screening over time, particularly in older age groups. Importantly, anal cytology performed poorly as a triage test for HRA referral, with high rates of “unsatisfactory” samples and low sensitivity for detecting HSIL.

3 November 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
CRCharlotte Rolle
Charlotte Rolle
AAAmit Achhra
Amit Achhra
CHChristina Harbison
Christina Harbison
DFDiana Finkel
Diana Finkel
CLChristopher Lucasti
Christopher Lucasti
JSJihad Slim
Jihad Slim
Background: Some individuals with human immunodeficiency virus (HIV-1) have acquired multidrug-resistant (MDR) strains of HIV and/or are nonadherent to antiretroviral (ARV) medication. Injectable ARVs can provide salvage therapy for those with limited therapeutic options and may be preferred by some people with HIV (PWH). Real-world evidence may contribute to a more comprehensive understanding of the barriers to adherence and the utility of injectable ARVs in PWH. Currently, there is a lack of data on combined use of injectable ibalizumab (IBA) and lenacapavir (LEN) with optimized background regimen (OBR). Methods: A retrospective observational study examined medical charts from people with MDR HIV across 8 facilities in the United States. All PWH used a combination of both IBA + LEN ± OBR for at least 6 months. Viral loads and CD4+ counts were collected. Results: A total of 21 PWH were included. Four-class resistance at baseline was reported in 38.1% of PWH. Within 12 to 24 weeks of combined IBA + LEN treatment, a median reduction of −2710 copies/mL HIV RNA was observed. Median increase to CD4+ count was 67.5 cells/mm3 within 4 to 44 weeks of treatment initiation. Few intolerances required changes to treatment. Therapy with IBA + LEN continued for an average of 30 months and 20 months, respectively. Conclusions: In this small group of individuals with MDR HIV who were heavily treatment-experienced and/or faced adherence challenges, the use of IBA + LEN ± OBR was well tolerated and led to clinically significant reductions in viral loads and improvements in CD4+ counts.

15 August 2014 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
AAAmit C. Achhra
Amit C. Achhra
SPSanjay Pujari
Sanjay Pujari
JCJun Yong Choi
Jun Yong Choi
SKSuwimol Khusuwan
Suwimol Khusuwan
NKNguyen Van Kinh
Nguyen Van Kinh
MLMatthew G. Law
Matthew G. Law

22 March 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
EEEric I Elliott
Eric I Elliott
DSDaisy Smith
Daisy Smith
JLJonathan Lipscomb
Jonathan Lipscomb
BBBubu A Banini
Bubu A Banini
LMLindsay Meurer
Lindsay Meurer
AAAmit Achhra
Amit Achhra
The acute retroviral syndrome may present with diverse systemic manifestations and laboratory abnormalities. Here we present a rare case of primary human immunodeficiency virus (HIV) infection causing severe acute hepatitis. Liver histopathology demonstrated a pattern of lymphocytic inflammation consistent with acute hepatitis, high levels of HIV proviral DNA were detected within liver tissue, and immunofluorescence showed HIV p24 antigen within immune and parenchymal cells including hepatocytes. We review the literature pertaining to HIV infection of cell compartments within the liver and discuss the implications for HIV-associated acute liver disease.

1 October 2026 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
AAAmit C Achhra
Amit C Achhra
OOOnyema E Ogbuagu
Onyema E Ogbuagu
Doravirine/islatravir (DOR-ISL) as a new once-daily oral single-tablet regimen for human immunodeficiency virus (HIV) treatment: unmet need or paradox of choice?

2 June 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
CPCarlo Foppiano Palacios
Carlo Foppiano Palacios
AAAmit Achhra
Amit Achhra
LBLydia Barakat
Lydia Barakat
MVMichael Virata
Michael Virata
RHRitche Hao
Ritche Hao
MMMaricar Malinis
Maricar Malinis
We evaluated the effectiveness of annual LTBI screening via IGRA in people with HIV in non-endemic settings over 5 years. Out of 1898 patients with at least 2 IGRAs, only 12 developed new LTBI, highlighting the low yield of universal screening. Findings support targeted screening per current guidelines.